WO1995012679A1 - Anti-helminth vaccines - Google Patents
Anti-helminth vaccines Download PDFInfo
- Publication number
- WO1995012679A1 WO1995012679A1 PCT/GB1994/002411 GB9402411W WO9512679A1 WO 1995012679 A1 WO1995012679 A1 WO 1995012679A1 GB 9402411 W GB9402411 W GB 9402411W WO 9512679 A1 WO9512679 A1 WO 9512679A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- precursor
- functionally
- equivalent variant
- antigenic fragment
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 29
- 239000000427 antigen Substances 0.000 claims abstract description 80
- 102000036639 antigens Human genes 0.000 claims abstract description 80
- 108091007433 antigens Proteins 0.000 claims abstract description 80
- 244000000013 helminth Species 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 25
- 239000012634 fragment Substances 0.000 claims abstract description 24
- 239000002243 precursor Substances 0.000 claims abstract description 24
- 230000000890 antigenic effect Effects 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 230000001681 protective effect Effects 0.000 claims abstract description 18
- 230000028993 immune response Effects 0.000 claims abstract description 13
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 9
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 9
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 8
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 6
- 230000004952 protein activity Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 241000282414 Homo sapiens Species 0.000 claims description 20
- 239000003599 detergent Substances 0.000 claims description 19
- 244000045947 parasite Species 0.000 claims description 17
- 241000243974 Haemonchus contortus Species 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 12
- 239000002953 phosphate buffered saline Substances 0.000 claims description 12
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 10
- 241000243976 Haemonchus Species 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 239000002198 insoluble material Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000000287 crude extract Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 claims description 3
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims description 3
- 238000002523 gelfiltration Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 238000011097 chromatography purification Methods 0.000 claims 1
- 239000013599 cloning vector Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 abstract description 2
- 108090000279 Peptidyltransferases Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 19
- 241001494479 Pecora Species 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 241000244206 Nematoda Species 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241001135902 Peanut clump virus Species 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 241000282849 Ruminantia Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 108010008488 Glycylglycine Proteins 0.000 description 3
- 108010034145 Helminth Proteins Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000243795 Ostertagia Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 229940043257 glycylglycine Drugs 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000009304 pastoral farming Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 229940125575 vaccine candidate Drugs 0.000 description 3
- PDJMCBVRNSWEOY-UHFFFAOYSA-N 1-[3-(3-acetyl-2-hydroxy-4,6-dimethoxy-5-methylphenyl)-2-hydroxy-4,6-dimethoxy-5-methylphenyl]ethanone Chemical compound OC1=C(C(C)=O)C(OC)=C(C)C(OC)=C1C1=C(O)C(C(C)=O)=C(OC)C(C)=C1OC PDJMCBVRNSWEOY-UHFFFAOYSA-N 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000191771 Teladorsagia circumcincta Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- CNXZLZNEIYFZGU-UHFFFAOYSA-N n-(4-amino-2,5-diethoxyphenyl)benzamide Chemical compound C1=C(N)C(OCC)=CC(NC(=O)C=2C=CC=CC=2)=C1OCC CNXZLZNEIYFZGU-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000931178 Bunostomum Species 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241001126267 Cooperia oncophora Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001147669 Dictyocaulus viviparus Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- 241000243789 Metastrongyloidea Species 0.000 description 1
- 241000556230 Metastrongylus Species 0.000 description 1
- 241000243794 Ostertagia ostertagi Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to novel helminth parasite antigens and their use in the control of disease caused by helminth parasites, particularly parasitic nematodes of the gastro-intestinal tract of mammals.
- Helminth parasites particularly nematodes, infect or infest a wide range of animals, including man, and are a widespread and significant source of disease and ill-thrift, not only in animals, but also in man. Such parasites thus represent a considerable worldwide drain on economic resources. This is particularly true in animal husbandry, where parasite infections of grazing animals, such as sheep and cattle, are often difficult and expensive to control and may result in significant economic losses.
- parasitic helminths of economic importance include the various species of the following helminth families:- Trichcstrpngylus, Nematpdirus, Pictypcaulus, Cppperia, Ascaris, Dirofiioria. Trichuris, Strpngylus,
- H110D an integral membrane protein isolated from the gut of H.contortus and described by Munn in WO88/00835.
- H110D now represents the most promising vaccine candidate to date.
- Munn has also described and proposed as a vaccine, contortin, a helical polymeric extracellular protein associated with the luminal surface of H.contortus intestinal cells (Munn et al.. Parasitology £4.: 385-397, 1987) .
- H45 Haemonchus gut membrane protein with protective antigenic properties
- proteins such as H110D and H45 can be used as the basis for a vaccine against Haemonchus.
- helminth parasite vaccines and in particular for a vaccine which may be used across a broad range of helminth genera.
- the present invention accordingly seeks to provide novel antigens for use as helminth parasite vaccines and in particular as protective immunogens in the control of diseases caused by helminth parasites. More specifically, the present invention is based on the finding that extracts of H.contortus containing a membrane-associated protein having ⁇ -glutamyl- transpeptidase ( ⁇ GTP) activity are capable of conferring protective immunity in animals against Haemonchus. yGTP functions as a transporter of amino acids across biological membranes. It has also been observed that membrane-bound transporters of other biological molecules also have useful protective antigenic activity. Such proteins, when liberated from the membranes with which they are associated, for example by the use of detergents, are novel and of use in the manufacture of vaccines against helminth infections.
- ⁇ GTP ⁇ -glutamyl- transpeptidase
- the present invention thus provides a protective helminth parasite antigen which is characterised by possessing transport protein activity and which, in native form, is a membrane-associated protein, or a functionally-equivalent variant, or antigenic fragment or precursor thereof.
- the antigen has ⁇ -glutamyl- transpeptidase activity.
- a further aspect of the invention provides such protective antigens, and functionaly-equivalent variants, antigenic fragments or precursors thereof, for use in stimulating an immune response against helminth parasites in a human or non-human, preferably mammalian, especially preferably ruminant, animal.
- transport protein activity is used herein to describe protein which are involved in the active transport across biological membranes of biomolecule ⁇ such as amino acids, peptides, carbohydrates, cofactors, nucleotides or ions. Many specific transport proteins are known for the transport of amino acids and sugar, for example.
- a precursor for the antigen in question may be a larger protein which is processed, eg. by proteolysis, to yield the antigen per se.
- Such precursors may take the form of zymogens ie. inactive precursors of enzymes, activated by proteolytic cleavage, for example analogous to the pepsin/pepsinogen system or the well known zymogens involved in the blood clotting cascade.
- novel antigens of the invention are not recognised by sera from naturally immune animals. In other words, they are not normally, in native form, accessible to the immune system of the infected host and are thus "hidden”, “concealed” or “cryptic” antigens.
- protective antigens or “protective antigenic activity” as used herein defines those antigens and their fragments or precursors, capable of generating a host-protective, ie. immunogenic, immune response, that is a response by the host which leads to generation of immune effector molecules, antibodies or cells which damage, inhibit or kill the parasite and thereby "protect” the host from clinical or sub-clinical disease and loss of productivity.
- a protective immune response may commonly be manifested by the generation of antibodies which are able to inhibit the metabolic function of the parasite, leading to stunting, lack of egg production and/or death.
- “Functionally-equivalent” is used herein to define proteins related to or derived from the native protein, where the amino acid sequence has been modified by single or multiple amino acid substitution, addition and/or deletion and also sequences where the amino acids have been chemically modified, including by deglycosylation or glycosylation, but which nonetheless retain protective antigenic activity eg. are capable of raising host protective antibodies and/or functional immunity against the parasites.
- addition variants are included amino and/or carboxy terminal fusion proteins or pclypeptides, comprising an additional protein or polypeptide fused to the ⁇ -GTP antigen sequence.
- Such functionally-equivalent variants mentioned above include natural biological variations (eg. allelic variants or geographical variations within a species) and derivatives prepared using known techniques.
- functionally-equivalent proteins may be prepared either by chemical peptide synthesis or in recombinant form using the known techniques of site-directed mutagenesis, random mutagenesis, or enzymatic cleavage and/or ligation of nucleic acids.
- Functionally-equivalent variants according to the invention also include analogues in different parasite genera or species.
- ⁇ -GTP enzymes function to transport glutamic acid and other amino acids across cell membranes.
- Other specific transport proteins exist for the transport across membranes of other nutrients, including other amino acids, carbohydrates e.g. sugars and ions. Such proteins are involved for example in the nutrient assimilation process in the gut of mammals.
- ⁇ -GTP enzymes are known and described in mammals, although not much is yet known concerning equivalent enzymes in helminths.
- ⁇ -GTP-like activity may be assayed using ⁇ -glutamic acid p- nitroanilide/glycylglycine as substrate, or by other techniques known in the art e.g. histochemistry using y- glutamyl-4-methoxy-2-naphthylamide as substrate in the presence of glycylglycine and diazotized 4'-amino-2', 5' -diethoxybenzanilide (Fast blue BBN) on cryostat sections of frozen tissue by the method of Rutenburg et al. 1969 J. Histochem Cytochem 17, 517.
- the yGTP antigen of the invention exhibits an apparent molecular weight (Mr) of about 58,000, as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing and non- reducing conditions.
- the ⁇ -GTP antigens of the present invention are associated with the membranes of the helminth parasites.
- ⁇ -GTP-like activity may be localised in an integral membrane fraction, that is a fraction extractable with ionic detergents such as Triton X-100 or polyoxyethylene 9-lauryl ether (Thesit) , as well as in a fraction which is more loosely associated with cellular membranes, and which may be extracted with gentler detergents eg. polyoxyethylene sorbitan monolaurate (Tween 20) , (Triton, Thesit and Tween are Trade Marks) .
- ionic detergents such as Triton X-100 or polyoxyethylene 9-lauryl ether (Thesit)
- Tween 20 polyoxyethylene sorbitan monolaurate
- Tween 20 Triton, Thesit and Tween are Trade Marks
- antigens according to the invention may be obtained by extraction of helminth parasites using appropriate detergents.
- a further aspect of the invention thus provides a method for preparing the above-mentioned antigens of the invention which comprises the step of subjecting a crude extract of a helminth parasite to detergent extraction, eg. using Tween 20 or a like detergent, and recovering the solubilised proteins.
- the detergent extract may then be subjected to further purification using conventional procedures eg. centrifugation, selective precipitation, electrophoresis, chromatography and the like. Fractions containing the antigen of the invention may be identified by assaying for ⁇ -GTP activity using known techniques.
- the detergent extraction may take place using a stronger detergent, such as Thesit or Triton X-100, which is capable of solubilising integral membrane proteins.
- a stronger detergent such as Thesit or Triton X-100
- such detergents also extract the integral membrane antigens H110D and H45 mentioned above.
- Antigens obtainable by such methods form a further aspect of the invention.
- the crude extract of the helminth parasite may be prepared using conventional biochemical and surgical techniques eg. by homogenisation of the whole or a portion of the parasite.
- the parasites may be subjected to homogenisation in a suitable buffer or medium such as phosphate buffered saline (PBS) and the insoluble material (ie. the pellet) may be recovered by centrifugation, whereby to form the required crude extract.
- PBS phosphate buffered saline
- a suitable purification protocol for the antigens of the invention might comprise (i) homogenising adult parasite worms in PBS, recovering the PBS-insoluble material (eg. by centrifugation) , optionally repeating the PBS-washing step one or more times, (ii) extracting the PBS-insoluble material (ie. the pellet) with Tween 20 (eg. in PBS) , (iii) recovering the solubilised fraction containing the Tween-soluble proteins (ie. the supernatant) followed by (iv) ion exchange chromatography eg. on a Mono Q column, and/or gel filtration eg. using Superose.
- the invention can also be seen to provide use of a helminth parasite antigen as hereinbefore defined, and fragments, precursors and functionally-equivalent variants thereof, for the preparation of a vaccine composition for use in stimulating an immune response against helminth parasites in a human or non-human, animal.
- the invention also provides a vaccine composition for stimulating an immune response against helminth parasites in a human or non-human animal comprising one or more antigens, antigenic fragments, precursors or functionally-equivalent variants thereof, as defined above, together with a pharmaceutically acceptable carrier or diluent, and a method of stimulating an immune response against helminth parasites in a human or non-human animal, comprising administering to said animal a vaccine composition as defined above.
- the animal preferably is mammalian and more preferably a ruminant.
- Antigens according to the invention may be obtained from a range of helminth parasite genera.
- the helminths will be nematodes, especially preferably gastro-intestinal nematodes including for example HaemPIlChUS, Ostertagia and Trichostron ⁇ ylus.
- the term "Ostertagia” as used herein includes Teladorsa ⁇ ia sp.
- Such antigens may be used to prepare vaccines against a range of helminth parasites including any of those mentioned above.
- antigens of the invention may exert their host protective effects by raising inhibitory antibodies which inhibit the growth, maintenance and/or development of the parasite.
- Such antibodies and their antigen- binding fragments eg. F(ab) 2 , Fab and Fv fragments ie. fragments of the "variable" region of the antibody, which comprises the antigen binding site
- Such inhibitory antibodies may be raised by use of idiotypic antibodies.
- Anti-idiotypic antibodies may be used as immunogens in vaccines.
- the antigens may be prepared by recombinant DNA technology using standard techniques, such as those described for example by Sambrook et al. , 1989, (Molecular Cloning, a laboratory manual 2nd Edition, Cold Spring Harbor Press) .
- Nucleic acid molecules comprising a nucleotide sequence encoding the antigens of the invention thus form further aspects of the invention.
- Nucleic acid molecules according to the invention may be single or double stranded DNA, cDNA or RNA, preferably DNA, and include degenerate, substantially homologous and hybridising sequences which are capable of coding for the antigen or antigen fragment or precursor concerned.
- substantially homologous is meant sequences displaying at least 60%, preferably at least 70% or 80% sequence homology.
- Hybridising sequences included with the scope of the invention are those binding under non-stringent conditions (6 x SSC/50% formamide at room temperature) and washed under conditions of low stringency (2 x SSC, room temperature, more preferably 2 x SCC, 42 D C) or conditions of higher stringency eg.
- nucleotide sequences capable of encoding antigenically active antigens or antigen variants according to the invention may be obtained by using conventional methods well known in the art.
- Antigens according to the invention may be prepared in recombinant form by expression in a host cell containing a recombinant DNA molecule which comprises a nucleotide sequence as broadly defined above, operatively linked to an expression control sequence, or a recombinant DNA cloning vehicle or vector containing such a recombinant DNA molecule.
- Synthetic polypeptides expressed in this manner form a further aspect of this invention (the term "polypeptide" is used herein to include both full-length protein and shorter length peptide sequences) .
- the antigen so expressed may be a fusion polypeptide comprising all or a portion of an antigen according to the invention and an additional polypeptide coded for by the DNA of the recombinant molecule fused thereto.
- This may for example be ⁇ -galactosidase, glutathione-S-transferase, hepatitis core antigen or any of the other polypeptides commonly employed in fusion proteins in the art.
- aspects of the invention thus include cloning and expression vectors containing the DNA coding for an antigen of the invention and methods for preparing recombinant nucleic acid molecules according to the invention, comprising inserting nucleotide sequences encoding the antigen into vector nucleic acid, eg. vector DNA.
- expression vectors include appropriate control sequences such as for example translational (eg. start and stop codons, ribosomal binding sites) and transcriptional control elements (eg. promoter-operator regions, termination stop sequences) linked in matching reading frame with the nucleic acid molecules of the invention.
- Vectors according to the invention may include plasmids and viruses (including both bacteriophage and eukaryotic viruses) according to techniques well known and documented in the art, and may be expressed in a variety of different expression systems, also well known and documented in the art.
- Suitable viral vectors include baculovirus and also adenovirus and vaccinia viruses. Many other viral vectors are described in the art.
- the invention also includes transformed or transfected prokaryotic or eukaryotic host cells, or transgenic organisms containing a nucleic acid molecule according to the invention as defined above.
- host cells may for example include prokaryotic cells such as E.coli.
- eukaryotic cells such as yeasts or the baculovirus-insect cell system, transformed mammalian cells and transgenic animals and plants.
- transgenic nematodes see for example Fire, 1986, EMBO J., __.. 2673 for a discussion of a transgenic system for the nematode Caenorhabditis.
- a further aspect of the invention provides a method for preparing an antigen of the invention as hereinbefore defined, which comprises culturing a host cell containing a nucleic acid molecule encoding all or a portion of said antigen, under conditions whereby said antigen is expressed and recovering said antigen thus produced.
- antigens of the invention and functionally equivalent antigen variants may also be prepared by chemical means, such as the well known Merrifield solid phase synthesis procedure.
- Water soluble derivatives of the novel antigens discussed above form a further aspect of the invention.
- Such soluble forms may be obtained by proteolytic digestion, for example using the enzyme elastase.
- proteolytic digestion for example using the enzyme elastase.
- enzymic digestion of the antigens yields two fractions, a detergent soluble fraction (which remains with the membrane) and a water-soluble fraction.
- a vaccine composition may be prepared according to the invention by methods well known in the art of vaecine manufacture.
- Traditional vaccine formulations may comprise one or more antigens or antibodies according to the invention together, where appropriate, with one or more suitable adjuvants eg. aluminium hydroxide, saponin, quil A, or more purified forms thereof, uramyl dipeptide, mineral or vegetable oils, Novasomes or non-ionic block co-polymers or DEAE dextran, in the presence of one or more pharmaceutically acceptable carriers or diluents.
- suitable carriers include liquid media such as saline solution appropriate for use as vehicles to introduce the peptides or polypeptides into an animal or patient. Additional components such as preservatives may be included.
- An alternative vaccine formulation may comprise a virus or host cell eg. a microorganism (eg. vaccinia virus, adenovirus or Salmonella) which may be live, killed or attenuated, having inserted therein a nucleic acid molecule (eg. a DNA molecule) according to this invention for stimulation of an immune response directed against polypeptides encoded by the inserted nucleic acid molecule.
- a virus or host cell eg. a microorganism (eg. vaccinia virus, adenovirus or Salmonella) which may be live, killed or attenuated, having inserted therein a nucleic acid molecule (eg. a DNA molecule) according to this invention for stimulation of an immune response directed against polypeptides encoded by the inserted nucleic acid molecule.
- Administration of the vaccine composition may take place by any of the conventional routes, eg. orally or parenterally such as by intramuscular injection, optionally at intervals eg. two injections at a 7-35 day interval.
- the antigens may be used according to the invention in combination with other protective antigens obtained from the same or different parasite species.
- a vaccine composition according to the invention may comprise one or more of the antigens defined above together with the antigens HllOD and H45 mentioned above and/or glutathione s-transferase.
- Such a combined vaccine composition may contain smaller amounts of the various antigens than an individual vaccine preparation, containing just the antigen in question. Combined vaccines are beneficial where there is a likelihood that "adaptive selection" of the parasite may occur when a single antigen vaccine is used.
- Animals which may benefit from the present invention may be any human or non-human animal, but companion animals, particularly dogs and cats and domestic animals, especially ruminants are preferred. Particular mention may be made of sheep, cattle, pigs, deer and goats.
- Figure 1 shows H. contortus Tween extracted ⁇ GTP enriched fractions run on a 6-16% reducing SDS- polyacrylamide gel
- Figure 2 shows the results of an ⁇ -GTP sheep trial; average percentage change in packed cell volume (PCVs) . Abscissa shows days post infection; ordinate shows average percentage change in PCV; D Control group ⁇ GTP group;
- Figure 3 shows the results of an ⁇ -GTP sheep trial; average faecal egg output. Abscissa shows days post infection; ordinate shows average number of eggs per gram of faeces; D Control group ⁇ GTP group;
- Figure 4 shows the results of an ⁇ -GTP sheep trial; average plasma anti- ⁇ GTPEF-1 levels per sheep measured by ELISA. Abscissa days post infection; ordinate shows absorbance at 405 nm; D Control group ⁇ GTP group;
- Figure 5 shows the results of an ⁇ -GTP sheep trial; average worm numbers ⁇ Male worms ⁇ Female worms. Percentage reductions in male/female numbers with respect to controls are shown vertically above bars. Overall reductions are displayed horizontally.
- Figure 6 shows light micrographs of a) transverse cryosection of adult Haemonchus contortus and b) oblique cryosection of Cooperia oncophora stained for ⁇ GTP activity by the method of Regenburg et al.
- the red reaction product is seen as the dark band (arrowed) associated with the microvilli at the luminal surface of the intestine of each parasite. (Reaction product is also found in some regions of the genital tract of Haemonchus (not illustrated) .)
- FIG. 7 shows a flow diagram of the purification procedures of Example 1 hereinafter.
- Fractions containing high concentrations of polypeptides at 55-58kDa were pooled and concentrated to l-2mls using a Centriprep 10 concentrator (Amicon, USA) . This volume was applied directly to a Superose 6 HR16/50 FPLC column (Pharmacia) and elution was carried out with lOOmls of pbs at a flow rate of 0.25ml/min. Fractions were analysed and pooled selectively according to the presence of 1) 55-58kDa components on SDS-PAGE and 2) High ⁇ GTP enzyme activity (see below for assay details) . Following concentration to l-3mls and the addition of sodium azide to 0.02% protein concentrations were measured using the Pierce BCA assay.
- Thesit extracts were ultracentrifuged and the supernatant liquids were pooled and concentrated. This provided the starting material for the fractionation scheme summarised in Fig. 7.
- the buffer was exchanged using a PD10 column (Pharmacia, U.K.) into 5mM-sodium acetate pH 5.2, lOOmM-NaCl, lmM- CaCl 2 , lmM-MnCl 2 , 0.02% NaN 3 , containing 0.1%
- Thesit Con A buffer
- Con A-cross linked agarose column 5mM-sodium acetate pH 5.2, lOOmM-NaCl, lmM- CaCl 2 , lmM-MnCl 2 , 0.02% NaN 3 , containing 0.1%
- Thesit Con A buffer
- Con A-cross linked agarose column 5mM-sodium acetate pH 5.2, lOOmM-NaCl,
- Micro-ELISA plate (Dynatech Immulon 1, Virginia, USA) wells were each filled with 100 ⁇ l of Tris/HCl pH 9.0 plus l-10 ⁇ l of the fraction to be assayed. The plates were then pre-incubated at 37°C for 15 minutes prior to the addition of lOO ⁇ l of 2mM ⁇ glutamic acid p- nitroanilide/1.9mM glycyl-glycine per well. The time zero optical density (OD) at 405nm was then measured using an ELISA plate reader and the plates were then incubated at 37°C for 15-30 minutes. The final OD reading was then taken as before and the OD change per minute per milligram of protein calculated.
- OD optical density
- Fig 1 The result of the purification of the ⁇ GTPEF-1 is shown in Fig 1, the major protein band being present at approximately 58 kDa although other minor bands were visible at 90 and 130 kDa.
- ELISA measurements of anti- ⁇ GTPEF-1 antibody levels are shown in Fig 4.
- the ⁇ GTP group did contain specific antibodies against the material injected, but the plateau levels of these antibodies were never higher than 0.88 on average.
- the mean number of worms at slaughter and the percentage reductions in numbers with respect to controls, are shown in Fig 5.
- the ⁇ GTP group showed a greater reduction in male (32%) than female (26.5%) numbers, the overall reduction being 29%.
- ⁇ GTP activity is present on the intestinal microvilli of both Haemonchus contortus and CPPPeria PUCPPftPra at which site it would be accessible to ingested host antibodies.
- the formation of the reaction product is inhibited by the presence of the specific inhibitors of ⁇ GTP activity, ImM phenylmethylsulphonyl fluoride (pmsf) and 3M maleic acid.
- ⁇ GTP activity from the Thesit extracts of Haemonchus contortus of Example 1(b) has a pi in the range 4 to 8 with the peak of activity at 5.6.
- the ⁇ GTP activity can not be released from PBS- extracted membranes from Haemonchus by the proteolytic enzymes papain, elastase, trypsin, chymotrypsin or subtlisin used under conditions which release many other enzyme activities from the membranes.
Abstract
The present invention provides a protective helminth parasite antigen which is characterized by possessing transport protein activity and which, in native form, is a membrane-associated protein, or a functionally-equivalent variant, or antigenic fragment or precursor thereof, and its use in the stimulation of an immune response against helminth parasites in an animal. Preferably, the antigen has η-glutamyl transpeptidase activity.
Description
ANTI-HELMINTH VACCINES
This invention relates to novel helminth parasite antigens and their use in the control of disease caused by helminth parasites, particularly parasitic nematodes of the gastro-intestinal tract of mammals.
Helminth parasites, particularly nematodes, infect or infest a wide range of animals, including man, and are a widespread and significant source of disease and ill-thrift, not only in animals, but also in man. Such parasites thus represent a considerable worldwide drain on economic resources. This is particularly true in animal husbandry, where parasite infections of grazing animals, such as sheep and cattle, are often difficult and expensive to control and may result in significant economic losses.
Particular mention may be made in this regard of the blood-sucking nematode Haemonchus contortus, a parasite of ruminants, most notably sheep. Also worthy of particular mention from the economic viewpoint are the non-blood feeding nematodes Ostertagia ostertagi and Ostertagia (Teladprsagia) circumcincta (o. circumcincta has recently been reclassified as T.circumcincta , although the new name is not yet in wide usage) .
Other parasitic helminths of economic importance include the various species of the following helminth families:- Trichcstrpngylus, Nematpdirus, Pictypcaulus, Cppperia, Ascaris, Dirofiioria. Trichuris, Strpngylus,
Fasciola. Oesophaσostomum. Bunostomum and Metastrongylus. In addition to domestic livestock, pets and humans may also be infected, not infrequently with fatal results.
At present, control of helminth parasites of grazing livestock relies primarily on the use of anthelmintic drugs, combined with pasture management. Such techniques have not proved entirely satisfactory
however, due to their expense and inconvenience and to a rapid increase in drug resistance. Anthelmintic drugs need to be administered frequently and appropriate pasture management is often not possible on some farms and even where it is, it can place constraints on the best use of available grazing.
To overcome these problems, attempts have been made to achieve immunological means of control. Although there has been some success in identifying certain protective antigens as potential vaccine candidates, most notably in Haemonchus. this approach has proved difficult and, other than for the cattle lungworm Dictyocaulus Viviparus, has yet to come to commercial fruition.
The most success to date has been achieved with the protein doublet H110D, an integral membrane protein isolated from the gut of H.contortus and described by Munn in WO88/00835. H110D now represents the most promising vaccine candidate to date.
Munn has also described and proposed as a vaccine, contortin, a helical polymeric extracellular protein associated with the luminal surface of H.contortus intestinal cells (Munn et al.. Parasitology £4.: 385-397, 1987) .
A third Haemonchus gut membrane protein with protective antigenic properties has also been discovered and termed H45 (Munn and Smith, WO90/11086) .
Whilst proteins such as H110D and H45 can be used as the basis for a vaccine against Haemonchus. there is nonetheless a continuing need for new and improved helminth parasite vaccines and in particular for a vaccine which may be used across a broad range of helminth genera.
The present invention accordingly seeks to provide novel antigens for use as helminth parasite vaccines and in particular as protective immunogens in the control of diseases caused by helminth parasites.
More specifically, the present invention is based on the finding that extracts of H.contortus containing a membrane-associated protein having γ-glutamyl- transpeptidase (γGTP) activity are capable of conferring protective immunity in animals against Haemonchus. yGTP functions as a transporter of amino acids across biological membranes. It has also been observed that membrane-bound transporters of other biological molecules also have useful protective antigenic activity. Such proteins, when liberated from the membranes with which they are associated, for example by the use of detergents, are novel and of use in the manufacture of vaccines against helminth infections.
According to one aspect, the present invention thus provides a protective helminth parasite antigen which is characterised by possessing transport protein activity and which, in native form, is a membrane-associated protein, or a functionally-equivalent variant, or antigenic fragment or precursor thereof.
In a preferred aspect the antigen has γ-glutamyl- transpeptidase activity.
A further aspect of the invention provides such protective antigens, and functionaly-equivalent variants, antigenic fragments or precursors thereof, for use in stimulating an immune response against helminth parasites in a human or non-human, preferably mammalian, especially preferably ruminant, animal.
The term "transport protein activity" is used herein to describe protein which are involved in the active transport across biological membranes of biomoleculeε such as amino acids, peptides, carbohydrates, cofactors, nucleotides or ions. Many specific transport proteins are known for the transport of amino acids and sugar, for example.
A precursor for the antigen in question may be a larger protein which is processed, eg. by proteolysis, to yield the antigen per se. Such precursors may take
the form of zymogens ie. inactive precursors of enzymes, activated by proteolytic cleavage, for example analogous to the pepsin/pepsinogen system or the well known zymogens involved in the blood clotting cascade.
The novel antigens of the invention are not recognised by sera from naturally immune animals. In other words, they are not normally, in native form, accessible to the immune system of the infected host and are thus "hidden", "concealed" or "cryptic" antigens.
The term "protective antigens" or "protective antigenic activity" as used herein defines those antigens and their fragments or precursors, capable of generating a host-protective, ie. immunogenic, immune response, that is a response by the host which leads to generation of immune effector molecules, antibodies or cells which damage, inhibit or kill the parasite and thereby "protect" the host from clinical or sub-clinical disease and loss of productivity. Such a protective immune response may commonly be manifested by the generation of antibodies which are able to inhibit the metabolic function of the parasite, leading to stunting, lack of egg production and/or death.
As mentioned above, included within the scope of the invention are functionally-equivalent variants of the novel antigens and their fragments and precursors. "Functionally-equivalent" is used herein to define proteins related to or derived from the native protein, where the amino acid sequence has been modified by single or multiple amino acid substitution, addition and/or deletion and also sequences where the amino acids have been chemically modified, including by deglycosylation or glycosylation, but which nonetheless retain protective antigenic activity eg. are capable of raising host protective antibodies and/or functional immunity against the parasites. Within the meaning of "addition" variants are included amino and/or carboxy terminal fusion proteins or pclypeptides, comprising an
additional protein or polypeptide fused to the γ-GTP antigen sequence. Such functionally-equivalent variants mentioned above include natural biological variations (eg. allelic variants or geographical variations within a species) and derivatives prepared using known techniques. For example, functionally-equivalent proteins may be prepared either by chemical peptide synthesis or in recombinant form using the known techniques of site-directed mutagenesis, random mutagenesis, or enzymatic cleavage and/or ligation of nucleic acids. Functionally-equivalent variants according to the invention also include analogues in different parasite genera or species.
As mentioned above, γ-GTP enzymes function to transport glutamic acid and other amino acids across cell membranes. Other specific transport proteins exist for the transport across membranes of other nutrients, including other amino acids, carbohydrates e.g. sugars and ions. Such proteins are involved for example in the nutrient assimilation process in the gut of mammals.
Whilst, not wishing to be bound by theory, it is believed that blockage of such proteins by antibodies may contribute to the protective antigenic response.
A variety of γ-GTP enzymes are known and described in mammals, although not much is yet known concerning equivalent enzymes in helminths. γ-GTP-like activity may be assayed using γ-glutamic acid p- nitroanilide/glycylglycine as substrate, or by other techniques known in the art e.g. histochemistry using y- glutamyl-4-methoxy-2-naphthylamide as substrate in the presence of glycylglycine and diazotized 4'-amino-2', 5' -diethoxybenzanilide (Fast blue BBN) on cryostat sections of frozen tissue by the method of Rutenburg et al. 1969 J. Histochem Cytochem 17, 517.
In the case of the nematode worm Haemonchus contortus. the yGTP antigen of the invention exhibits an apparent molecular weight (Mr) of about 58,000, as
determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing and non- reducing conditions.
The γ-GTP antigens of the present invention are associated with the membranes of the helminth parasites. In particular, studies using various detergents have shown that γ-GTP-like activity may be localised in an integral membrane fraction, that is a fraction extractable with ionic detergents such as Triton X-100 or polyoxyethylene 9-lauryl ether (Thesit) , as well as in a fraction which is more loosely associated with cellular membranes, and which may be extracted with gentler detergents eg. polyoxyethylene sorbitan monolaurate (Tween 20) , (Triton, Thesit and Tween are Trade Marks) .
In the case of the helminth Haemonchus contortus it has been found that up to 74% of γ-GTP-like activity may be localised in a Thesit detergent soluble extract, and that about 16% may be localised in a Tween detergent soluble extract.
Thus, antigens according to the invention may be obtained by extraction of helminth parasites using appropriate detergents.
A further aspect of the invention thus provides a method for preparing the above-mentioned antigens of the invention which comprises the step of subjecting a crude extract of a helminth parasite to detergent extraction, eg. using Tween 20 or a like detergent, and recovering the solubilised proteins.
The detergent extract may then be subjected to further purification using conventional procedures eg. centrifugation, selective precipitation, electrophoresis, chromatography and the like. Fractions containing the antigen of the invention may be identified by assaying for γ-GTP activity using known techniques.
Alternatively, the detergent extraction may take
place using a stronger detergent, such as Thesit or Triton X-100, which is capable of solubilising integral membrane proteins. In the case of Haemonchus. this is less preferred however, as such detergents also extract the integral membrane antigens H110D and H45 mentioned above.
Antigens obtainable by such methods form a further aspect of the invention.
The crude extract of the helminth parasite may be prepared using conventional biochemical and surgical techniques eg. by homogenisation of the whole or a portion of the parasite. Thus, for example the parasites may be subjected to homogenisation in a suitable buffer or medium such as phosphate buffered saline (PBS) and the insoluble material (ie. the pellet) may be recovered by centrifugation, whereby to form the required crude extract.
Thus, a suitable purification protocol for the antigens of the invention might comprise (i) homogenising adult parasite worms in PBS, recovering the PBS-insoluble material (eg. by centrifugation) , optionally repeating the PBS-washing step one or more times, (ii) extracting the PBS-insoluble material (ie. the pellet) with Tween 20 (eg. in PBS) , (iii) recovering the solubilised fraction containing the Tween-soluble proteins (ie. the supernatant) followed by (iv) ion exchange chromatography eg. on a Mono Q column, and/or gel filtration eg. using Superose.
Protection trials using antigens prepared either by Tween or by Thesit extraction have shown that immunity may be induced in sheep against challenge by H.contortus. It has been observed in this regard that a greater effect is achieved against male worms than female worms. This is opposite to the effect observed with the antigen H110D, and means for example that the antigens of the invention have utility in augmenting the effects of H110D eg. in a combined vaccine.
Viewed from a different aspect, the invention can also be seen to provide use of a helminth parasite antigen as hereinbefore defined, and fragments, precursors and functionally-equivalent variants thereof, for the preparation of a vaccine composition for use in stimulating an immune response against helminth parasites in a human or non-human, animal.
The invention also provides a vaccine composition for stimulating an immune response against helminth parasites in a human or non-human animal comprising one or more antigens, antigenic fragments, precursors or functionally-equivalent variants thereof, as defined above, together with a pharmaceutically acceptable carrier or diluent, and a method of stimulating an immune response against helminth parasites in a human or non-human animal, comprising administering to said animal a vaccine composition as defined above.
The animal preferably is mammalian and more preferably a ruminant.
Antigens according to the invention may be obtained from a range of helminth parasite genera. Preferably, however the helminths will be nematodes, especially preferably gastro-intestinal nematodes including for example HaemPIlChUS, Ostertagia and Trichostronσylus. (For the avoidance of doubt, the term "Ostertagia" as used herein includes Teladorsaσia sp.) Such antigens may be used to prepare vaccines against a range of helminth parasites including any of those mentioned above. Preferred are those antigens, so called "broad spectrum" antigens, which are capable of stimulating host protective immune responses against, in addition to the parasite from which they were isolated, a broad range of other parasites.
As mentioned above, one of the ways in which the antigens of the invention may exert their host protective effects is by raising inhibitory antibodies which inhibit the growth, maintenance and/or development
of the parasite. Such antibodies and their antigen- binding fragments (eg. F(ab)2, Fab and Fv fragments ie. fragments of the "variable" region of the antibody, which comprises the antigen binding site) which may be mono- or polyclonal, form a further aspect of the invention, as do vaccine compositions containing them and their use in the preparation of vaccine compositions for use in immunising hosts against parasites. Such inhibitory antibodies may be raised by use of idiotypic antibodies. Anti-idiotypic antibodies may be used as immunogens in vaccines.
In addition to the extraction and isolation techniques mentioned above, the antigens may be prepared by recombinant DNA technology using standard techniques, such as those described for example by Sambrook et al. , 1989, (Molecular Cloning, a laboratory manual 2nd Edition, Cold Spring Harbor Press) .
Nucleic acid molecules comprising a nucleotide sequence encoding the antigens of the invention thus form further aspects of the invention.
Nucleic acid molecules according to the invention may be single or double stranded DNA, cDNA or RNA, preferably DNA, and include degenerate, substantially homologous and hybridising sequences which are capable of coding for the antigen or antigen fragment or precursor concerned. By "substantially homologous" is meant sequences displaying at least 60%, preferably at least 70% or 80% sequence homology. Hybridising sequences included with the scope of the invention are those binding under non-stringent conditions (6 x SSC/50% formamide at room temperature) and washed under conditions of low stringency (2 x SSC, room temperature, more preferably 2 x SCC, 42DC) or conditions of higher stringency eg. 2 x SSC, 65°C (where SSC = 0.15M NaCl, 0.015M sodium citrate, pH 7.2), as well as those which, but for the degenerary of the code, would hybridise under the above-mentioned conditions.
Derivatives of nucleotide sequences capable of encoding antigenically active antigens or antigen variants according to the invention may be obtained by using conventional methods well known in the art.
Antigens according to the invention may be prepared in recombinant form by expression in a host cell containing a recombinant DNA molecule which comprises a nucleotide sequence as broadly defined above, operatively linked to an expression control sequence, or a recombinant DNA cloning vehicle or vector containing such a recombinant DNA molecule. Synthetic polypeptides expressed in this manner form a further aspect of this invention (the term "polypeptide" is used herein to include both full-length protein and shorter length peptide sequences) .
The antigen so expressed may be a fusion polypeptide comprising all or a portion of an antigen according to the invention and an additional polypeptide coded for by the DNA of the recombinant molecule fused thereto. This may for example be β-galactosidase, glutathione-S-transferase, hepatitis core antigen or any of the other polypeptides commonly employed in fusion proteins in the art.
Other aspects of the invention thus include cloning and expression vectors containing the DNA coding for an antigen of the invention and methods for preparing recombinant nucleic acid molecules according to the invention, comprising inserting nucleotide sequences encoding the antigen into vector nucleic acid, eg. vector DNA. Such expression vectors include appropriate control sequences such as for example translational (eg. start and stop codons, ribosomal binding sites) and transcriptional control elements (eg. promoter-operator regions, termination stop sequences) linked in matching reading frame with the nucleic acid molecules of the invention.
Vectors according to the invention may include
plasmids and viruses (including both bacteriophage and eukaryotic viruses) according to techniques well known and documented in the art, and may be expressed in a variety of different expression systems, also well known and documented in the art. Suitable viral vectors include baculovirus and also adenovirus and vaccinia viruses. Many other viral vectors are described in the art.
A variety of techniques are known and may be used to introduce such vectors into prokaryotic or eukaryotic cells for expression, or into germ line or somatic cells to form transgenic animals. Suitable transformation or transfection techniques are well described in the literature.
The invention also includes transformed or transfected prokaryotic or eukaryotic host cells, or transgenic organisms containing a nucleic acid molecule according to the invention as defined above. Such host cells may for example include prokaryotic cells such as E.coli. eukaryotic cells such as yeasts or the baculovirus-insect cell system, transformed mammalian cells and transgenic animals and plants. Particular mention may be made of transgenic nematodes (see for example Fire, 1986, EMBO J., __.. 2673 for a discussion of a transgenic system for the nematode Caenorhabditis) .
A further aspect of the invention provides a method for preparing an antigen of the invention as hereinbefore defined, which comprises culturing a host cell containing a nucleic acid molecule encoding all or a portion of said antigen, under conditions whereby said antigen is expressed and recovering said antigen thus produced.
The antigens of the invention and functionally equivalent antigen variants may also be prepared by chemical means, such as the well known Merrifield solid phase synthesis procedure.
Water soluble derivatives of the novel antigens
discussed above form a further aspect of the invention. Such soluble forms may be obtained by proteolytic digestion, for example using the enzyme elastase. Generally speaking enzymic digestion of the antigens yields two fractions, a detergent soluble fraction (which remains with the membrane) and a water-soluble fraction.
A vaccine composition may be prepared according to the invention by methods well known in the art of vaecine manufacture. Traditional vaccine formulations may comprise one or more antigens or antibodies according to the invention together, where appropriate, with one or more suitable adjuvants eg. aluminium hydroxide, saponin, quil A, or more purified forms thereof, uramyl dipeptide, mineral or vegetable oils, Novasomes or non-ionic block co-polymers or DEAE dextran, in the presence of one or more pharmaceutically acceptable carriers or diluents. Suitable carriers include liquid media such as saline solution appropriate for use as vehicles to introduce the peptides or polypeptides into an animal or patient. Additional components such as preservatives may be included.
An alternative vaccine formulation may comprise a virus or host cell eg. a microorganism (eg. vaccinia virus, adenovirus or Salmonella) which may be live, killed or attenuated, having inserted therein a nucleic acid molecule (eg. a DNA molecule) according to this invention for stimulation of an immune response directed against polypeptides encoded by the inserted nucleic acid molecule.
Administration of the vaccine composition may take place by any of the conventional routes, eg. orally or parenterally such as by intramuscular injection, optionally at intervals eg. two injections at a 7-35 day interval.
The antigens may be used according to the invention in combination with other protective antigens obtained
from the same or different parasite species. Thus a vaccine composition according to the invention may comprise one or more of the antigens defined above together with the antigens HllOD and H45 mentioned above and/or glutathione s-transferase. Such a combined vaccine composition may contain smaller amounts of the various antigens than an individual vaccine preparation, containing just the antigen in question. Combined vaccines are beneficial where there is a likelihood that "adaptive selection" of the parasite may occur when a single antigen vaccine is used.
Animals which may benefit from the present invention may be any human or non-human animal, but companion animals, particularly dogs and cats and domestic animals, especially ruminants are preferred. Particular mention may be made of sheep, cattle, pigs, deer and goats.
The invention will now be described further in the following non-limiting Example in which:
Figure 1 shows H. contortus Tween extracted γGTP enriched fractions run on a 6-16% reducing SDS- polyacrylamide gel
1. Fractions purified by ion exchange (Mono Q) and
2. Gel filtration (Superose 6) and selected for high γGTP activity. Contaminants A &B present - MWs of 130,000 and 90,000.
3. Molecular weight markers;
Figure 2 shows the results of an γ-GTP sheep trial; average percentage change in packed cell volume (PCVs) . Abscissa shows days post infection; ordinate shows average percentage change in PCV; D Control group Δ GTP group;
Figure 3 shows the results of an γ-GTP sheep trial;
average faecal egg output. Abscissa shows days post infection; ordinate shows average number of eggs per gram of faeces; D Control group Δ GTP group;
Figure 4 shows the results of an γ-GTP sheep trial; average plasma anti-γGTPEF-1 levels per sheep measured by ELISA. Abscissa days post infection; ordinate shows absorbance at 405 nm; D Control group Δ GTP group;
Figure 5 shows the results of an γ-GTP sheep trial; average worm numbers ■ Male worms □ Female worms. Percentage reductions in male/female numbers with respect to controls are shown vertically above bars. Overall reductions are displayed horizontally.
Figure 6 shows light micrographs of a) transverse cryosection of adult Haemonchus contortus and b) oblique cryosection of Cooperia oncophora stained for γGTP activity by the method of Regenburg et al. The red reaction product is seen as the dark band (arrowed) associated with the microvilli at the luminal surface of the intestine of each parasite. (Reaction product is also found in some regions of the genital tract of Haemonchus (not illustrated) .)
Figure 7 shows a flow diagram of the purification procedures of Example 1 hereinafter.
Example 1
Materials anfl methcds
(a) Production of a γGTP enriched fraction (γGTPEF 1)
Adult Haemonchus contortus were homogenized in ice- cold phosphate buffered saline (pbs; 0.15M, pH7.2) containing 0.02% sodium azide in a Potter-Elvehjeim
homogenizer. The suspension was then spun at 17,000g and the pellet resuspended in pbs azide. The washing process was repeated except that the pellet was resuspended in ice cold pbs containing 0.02% sodium azide and 1% Tween 20. Following a final spin at 17,000g the supernatant was removed and concentrated by polyethylene glycol 20,000 dialysis to a volume of 50mls or less and dialysed into MonoQ (Pharmacia) buffer A (20mM Tris/HCl pH 7.2, containing 0.1% Tween 20) . The samples were applied to a MonoQ HR5/5 (FPLC) column in 10-30ml batches and bound protein was separated with a 0-40% gradient of MonoQ buffer B (buffer A plus 1M sodium chloride) over 40mls at a flow rate of 0.7mls/min. Fractions containing high concentrations of polypeptides at 55-58kDa (judged by reducing SDS-PAGE) were pooled and concentrated to l-2mls using a Centriprep 10 concentrator (Amicon, USA) . This volume was applied directly to a Superose 6 HR16/50 FPLC column (Pharmacia) and elution was carried out with lOOmls of pbs at a flow rate of 0.25ml/min. Fractions were analysed and pooled selectively according to the presence of 1) 55-58kDa components on SDS-PAGE and 2) High γGTP enzyme activity (see below for assay details) . Following concentration to l-3mls and the addition of sodium azide to 0.02% protein concentrations were measured using the Pierce BCA assay.
(b) Production of a further v-GTP enriched fraction (γ- GTP 2 )
Adult Haemonchus contortus were obtained and extracted as described by Munn, Smith, Graham, Tavernor & Greenwood (1993), Int Journal for Parasitology 23, 261-269. Briefly, adult Haemonchus stored at -20°C in approximately their own weight of PBS containing 0.02% NaN3 (PBS/a) were thawed and then homogenized in ice-cold PBS/a. The homogenate was centrifuged and the pellets were re-extracted with PBS/a. The pellets were then
extracted with 1% Tween 20 followed by 1% Thesit (polyoxyethylene 9 lauryl ether, Boehringer Mannheim GmbH) in PBS/a. The Thesit extracts were ultracentrifuged and the supernatant liquids were pooled and concentrated. This provided the starting material for the fractionation scheme summarised in Fig. 7. The buffer was exchanged using a PD10 column (Pharmacia, U.K.) into 5mM-sodium acetate pH 5.2, lOOmM-NaCl, lmM- CaCl2, lmM-MnCl2, 0.02% NaN3, containing 0.1% Thesit (Con A buffer) and the solution applied to a Con A-cross linked agarose column. Glycosylated proteins binding to the Con A were eluted with 500mM-methyl α-D- glucopyranoside in Con A buffer. Portions of this fraction were buffer exchanged into 20mM-Tris/HCl pH 7.2 containing 0.1% Thesit and applied to a Mono Q anion exchange column (Pharmacia) . Proteins not binding to the column did not contain γGTP activity. Bound proteins were eluted from the Mono Q with lM-NaCl in 20mM-Tris/HCl, pH7.2, 0.1% Thesit, first as a 0-25% gradient and then 100%. Fractions coinciding with the u.v. absorption peaks were run on SDS-PAGE and assayed for γGTP activity.
(c) Measurement of γGTP enzyme activity usinσ a microplate assay
Micro-ELISA plate (Dynatech Immulon 1, Virginia, USA) wells were each filled with 100μl of Tris/HCl pH 9.0 plus l-10μl of the fraction to be assayed. The plates were then pre-incubated at 37°C for 15 minutes prior to the addition of lOOμl of 2mM γglutamic acid p- nitroanilide/1.9mM glycyl-glycine per well. The time zero optical density (OD) at 405nm was then measured using an ELISA plate reader and the plates were then incubated at 37°C for 15-30 minutes. The final OD reading was then taken as before and the OD change per
minute per milligram of protein calculated.
(d) vGTP vaccine trial
Six sheep of 3.75-5.5 months of age were assigned to each group and were each given 3 injections of γGTPEF-1. PCVs, faecal egg counts, collection of plasma, ELISAs, post mortem procedure, worm collection and weight/numbers calculation were all carried out according to standard operating procedures.
Results
The result of the purification of the γGTPEF-1 is shown in Fig 1, the major protein band being present at approximately 58 kDa although other minor bands were visible at 90 and 130 kDa.
Changes in PCVs of the groups over the duration of the experiment are shown as percentages of pre-infection values in Fig 2. The most substantial fall in PCV was seen in the control group whilst levels in the γGTPEF-1 group were less affected.
Average faecal egg counts for both groups at time points throughout the experiment are shown in 3. The γGTP group showed a considerable (>50%) reduction in egg output with respect to controls from 21 DPI.
ELISA measurements of anti-γGTPEF-1 antibody levels are shown in Fig 4. The γGTP group did contain specific antibodies against the material injected, but the plateau levels of these antibodies were never higher than 0.88 on average.
The mean number of worms at slaughter and the percentage reductions in numbers with respect to
controls, are shown in Fig 5. The γGTP group showed a greater reduction in male (32%) than female (26.5%) numbers, the overall reduction being 29%.
The results show that γGTPEF-l is a good vaccine candidate.
Example 2
As shown in Figure 6, it may be demonstrated by appropriate histochemical procedures that γGTP activity is present on the intestinal microvilli of both Haemonchus contortus and CPPPeria PUCPPftPra at which site it would be accessible to ingested host antibodies. The formation of the reaction product is inhibited by the presence of the specific inhibitors of γGTP activity, ImM phenylmethylsulphonyl fluoride (pmsf) and 3M maleic acid.
Example 3
By free-flow isoelectric focussing, γGTP activity from the Thesit extracts of Haemonchus contortus of Example 1(b) has a pi in the range 4 to 8 with the peak of activity at 5.6. Antibodies from sheep injected with fractions including this range of pis, obtained by isoelectric focussing, inhibit the in vitro activity, assayed as described above, of γGTP by 70% whereas antibodies from control sheep (injected with horse spleen ferritin) inhibit the γGTP activity by only 17%.
The γGTP activity can not be released from PBS- extracted membranes from Haemonchus by the proteolytic enzymes papain, elastase, trypsin, chymotrypsin or subtlisin used under conditions which release many other enzyme activities from the membranes.
Claims
1. A protective helminth parasite antigen which is characterised by possessing transport protein activity and which, in native form, is a membrane-associated protein, or a functionally-equivalent variant, or antigenic fragment or precursor thereof.
2. An antigen as claimed in claim 1, and functionally- equivalent variants, antigenic fragments or precursors thereof, for use in stimulating an immune response against helminth parasites in a human or non-human animal.
3. An antigen as claimed in claim 1 or claim 2 having γ-glutamyl transpeptidase activity, or a functionally equivalent variant, antigenic fragment or precursor thereof.
4. An antigen as claimed in any one of claims 1 to 3, which is isolatable from helminths of the genera Haemonchus. Os ertaσia or Trichostronσylns. or a functionally equivalent variant, antigenic fragment or precursor thereof.
5. An antigen as claimed in any one of claims 1 to 4, or a functionally equivalent variant, antigenic fragment or precursor thereof, which antigen is obtainable from Haemonchus contortus and has an apparent molecular weight (Mr) of about 58,000, as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) under reducing and non-reducing conditions.
6. An antigen as claimed in any one of claims 1 to 5, which is a membrane-associated protein extractable with the detergent polyoxyethylene sorbitan monolaurate, or a functionally equivalent variant, antigenic fragment or precursor thereof.
7. An antigen as claimed in any one of claims 1 to 5, which is an integral membrane protein or a functionally equivalent variant, antigenic fragment or precursor thereof.
8. A method for preparing an antigen, or a functionally equivalent variant, antigenic fragment or precursor thereof as defined in any one of claims 1 to 7, said method comprising the step of subjecting a crude extract of a helminth parasite to detergent extraction, and recovering the solubilised proteins.
9. A method as claimed in claim 8, wherein the detergent is a non-ionic detergent.
10. A method as claimed in claim 8, wherein the detergent is polyoxyethylene sorbitan monolaurate.
11. A method as claimed in any one of claims 8 to 10, further comprising one or more additional chromatographic purification steps.
12. A method as claimed in any one of claims 8, 10 and 11 comprising
(i) homogenising adult parasite worms in phosphate buffered saline (PBS) , recovering the PBS-insoluble material, optionally repeating the PBS-washing step one or more times,
(ii) extracting the PBS-insoluble material with Tween 20,
(iii) recovering the solubilised fraction containing the Tween-soluble proteins followed by
(iv) ion exchange chromatography, and/or gel filtration.
13. Use of a helminth parasite antigen as claimed in any one of claims 1 to 7, or a fragment, precursor or functionally-equivalent variant thereof, for the preparation of a vaccine composition for use in stimulating an immune response against helminth parasites in a human or non-human animal.
14. A vaccine composition for stimulating an immune response against helminth parasites in a human or non- human animal comprising one or more antigens, antigenic fragments, precursors or functionally-equivalent variants thereof, as claimed in any one of claims 1 to 7, together with a pharmaceutically acceptable carrier or diluent.
15. A method of stimulating an immune response against helminth parasites in a human or non-human animal, comprising administering to said animal a vaccine composition as claimed in claim 14.
16. An antibody, or antigen-binding fragment thereof, which is capable of selectively binding either to an antigen, antigenic fragment, precursor or functionally- equivalent variant thereof as defined in any one of claims 1 to 7, or to the idiotype of a said antigen- binding antibody.
17. A nucleic acid molecule comprising a nucleotide sequence encoding an antigen, functionally equivalent variant, antigenic fragment or precursor thereof, as claimed in any one of claims 1 to 7.
18. An expression or cloning vector comprising a nucleic acid molecule as defined in claim 17.
19. A host cell or transgenic organism containing a nucleic acid molecule as defined in claim 17..
20. A method for preparing an antigen, antigenic fragment, precursor, or functionally equivalent variant thereof, as defined in any one of claims 1 to 7, which comprises culturing a host cell containing a nucleic acid molecule encoding all or a portion of said antigen, under conditions whereby said antigen is expressed and recovering said antigen thus produced.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU80648/94A AU8064894A (en) | 1993-11-05 | 1994-11-03 | Anti-helminth vaccines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939322808A GB9322808D0 (en) | 1993-11-05 | 1993-11-05 | Vaccines |
GB9322808.8 | 1993-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995012679A1 true WO1995012679A1 (en) | 1995-05-11 |
Family
ID=10744680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1994/002411 WO1995012679A1 (en) | 1993-11-05 | 1994-11-03 | Anti-helminth vaccines |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU8064894A (en) |
GB (1) | GB9322808D0 (en) |
WO (1) | WO1995012679A1 (en) |
ZA (1) | ZA948729B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001550A2 (en) * | 1996-07-04 | 1998-01-15 | Universiteit Utrecht | Vaccine against gastro-intestinal nematodes |
GB2285626B (en) * | 1993-12-16 | 1998-04-15 | Fundacao Oswaldo Cruz | Schistosoma mansoni sm14 antigen for use in vaccination |
WO1998015625A1 (en) * | 1996-10-10 | 1998-04-16 | Bayer Aktiengesellschaft | Nematode proteins, dna sequences coding therefor, their specific antibodies and their use in identifying nematicidal active substances |
-
1993
- 1993-11-05 GB GB939322808A patent/GB9322808D0/en active Pending
-
1994
- 1994-11-03 AU AU80648/94A patent/AU8064894A/en not_active Abandoned
- 1994-11-03 WO PCT/GB1994/002411 patent/WO1995012679A1/en active Application Filing
- 1994-11-04 ZA ZA948729A patent/ZA948729B/en unknown
Non-Patent Citations (7)
Title |
---|
BIOCHEM.PARASITES HOST-PARASITE RELAT.,PROC.INT.SYMP.,2ND, 1976, pages 101 - 107 * |
CHEMICAL ABSTRACTS, vol. 105, no. 19, 10 November 1986, Columbus, Ohio, US; abstract no. 169243d, DASS ET AL: "GAMMA-GLUTAMYL TRANSPEPTIDASE ACTIVITY IN ASCARIS SUUM" page 465; column 1; * |
CHEMICAL ABSTRACTS, vol. 87, no. 11, 12 September 1977, Columbus, Ohio, US; abstract no. 81521s, KURELEC ET AL: "OCCURENCE OF GAMMA-GLUTAMYL CYCLE IN SOME PARASITIC HELMINTHS" page 313; column 1; * |
LINCKE ET AL: "THE EXPRESSION OF TWO P-GLYCOPROTEIN (PGP) GENES IN TRANSGENIC CAENORHABDITIS ELEGANS IS CONFINED TO INTESTINAL CELLS", THE EMBO JOURNAL, vol. 12, no. 4, April 1993 (1993-04-01), OXFORD,GB, pages 1615 - 1620 * |
MOL.BIOCHEM.PARASITOL., vol. 20, no. 3, 1986, pages 233 - 236 * |
SKELLY ET AL: "CLONING,CHARACTERIZATION,AND FUNCTIONAL EXPRESSION OF CDNAS ENCODING GLUCOSE TRANSPORTER PROTEINS FROM THE HUMAN PARASITE SCHISTOSOMA MANSONI", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 6, 11 February 1994 (1994-02-11), BALTIMORE,USA, pages 4247 - 4253 * |
SMITH ET AL: "PURIFICATION ADN EVALUATION OF THE INTEGRAL MEMBRANE PROTEIN H11 AS A PROTECTIVE ANTIGEN AGAINST HAEMONCHUS CONTORTUS", INTERNATIONAL JOURNAL FOR PARASITOLOGY, vol. 23, no. 2, April 1993 (1993-04-01), OXFORD,GB, pages 271 - 280 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2285626B (en) * | 1993-12-16 | 1998-04-15 | Fundacao Oswaldo Cruz | Schistosoma mansoni sm14 antigen for use in vaccination |
WO1998001550A2 (en) * | 1996-07-04 | 1998-01-15 | Universiteit Utrecht | Vaccine against gastro-intestinal nematodes |
WO1998001550A3 (en) * | 1996-07-04 | 1998-05-28 | Univ Utrecht | Vaccine against gastro-intestinal nematodes |
WO1998015625A1 (en) * | 1996-10-10 | 1998-04-16 | Bayer Aktiengesellschaft | Nematode proteins, dna sequences coding therefor, their specific antibodies and their use in identifying nematicidal active substances |
Also Published As
Publication number | Publication date |
---|---|
ZA948729B (en) | 1995-07-10 |
GB9322808D0 (en) | 1993-12-22 |
AU8064894A (en) | 1995-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Piacenza et al. | Vaccination with cathepsin L proteinases and with leucine aminopeptidase induces high levels of protection against fascioliasis in sheep | |
CA1340301C (en) | Vaccines against animal parasitic nematodes | |
Tsuda et al. | cDNA cloning, characterization and vaccine effect analysis of Haemaphysalis longicornis tick saliva proteins | |
Ellis et al. | Evaluation of recombinant proteins of Neospora caninum as vaccine candidates (in a mouse model) | |
JPH025871A (en) | Recombinant and natural a, c, f and h group eimeria tenera immunogen useful as coccidiosis vaccine | |
Claerebout et al. | Current research and future prospects in the development of vaccines against gastrointestinal nematodes in cattle | |
US6623735B1 (en) | Vaccine containing a thiol protease | |
AU675443B2 (en) | Vaccines against metazoan parasites | |
WO1995012679A1 (en) | Anti-helminth vaccines | |
EP0434909A2 (en) | Anticoagulant and antihelminthic proteins and methods for the production and use of same | |
US6413521B1 (en) | Helminth parasite antigen with aminopeptidase-like activity | |
WO1994017820A1 (en) | Polypeptides obtainable from species of fasciola, and vaccines, methods of treatment and dna sequences of the same | |
JP4321881B2 (en) | In vitro animal or attack model for protective immunity assay against parasite and vaccine showing protective action in the method | |
US5843710A (en) | Vaccines against animal parasitic nematodes | |
AU701642B2 (en) | Vaccines against helminthic parasites | |
GB2285626A (en) | Antigenic protein from Schistosoma mansoni | |
EP0646015B1 (en) | Contraceptive vaccine | |
US20030129204A1 (en) | Vaccines against helminthic parasites | |
CA2172492A1 (en) | Protective antigens against parasites | |
AU731026B2 (en) | Vaccine containing a thiol protease | |
MXPA03009306A (en) | Antigens for raising an immune response against rickettsieae and ehrlichieae pathogens. | |
JP4048271B2 (en) | Parasite inorganic pyrophosphatase, nucleic acid molecule encoding the same, and use thereof | |
WO1995027056A1 (en) | Parasite immunoglobulin binding proteins, and their use as vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |